Hypertension: history and development of established and novel treatments

Milan Wolf1, Sebastian Ewen1, Felix Mahfoud1

  • 1Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Universität des Saarlandes, Angiologie und Internistische Intensivmedizin, Kirrberger Str. 1, 66421, Homburg, Saar, Germany.

Insights

Hypertension management has evolved significantly, from an undefined condition to a key modifiable cardiovascular risk factor. Ongoing research focuses on novel drug and device therapies to further reduce cardiovascular events.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Hypertension (high blood pressure) has transitioned from an ill-defined condition to a primary modifiable cardiovascular risk factor.
  • Significant advancements in drug and interventional treatments have been made over recent decades.
  • The evolving understanding of hypertension impacts cardiovascular outcome strategies.

Purpose of the Study:

  • To summarize the historical development and paradigm shifts in the field of hypertension.
  • To review the evolution of drug and interventional treatments for hypertension.
  • To discuss current and future therapeutic strategies for improving cardiovascular outcomes in hypertensive patients.

Main Methods:

  • A selective literature search was conducted in PubMed.
  • The search included trials published up to 2018 without time restrictions.
  • Unpublished trials from ClinicalTrials.gov were also incorporated.

Main Results:

  • Hypertension treatment has progressed significantly, marked by the development of effective and tolerable medications.
  • Interventional techniques such as renal denervation, arteriovenous fistulas, and autonomic devices represent novel therapeutic approaches.
  • New hypertension guidelines have introduced revised definitions and treatment targets, sparking ongoing debate.

Conclusions:

  • Despite effective drug therapies, research continues into novel treatments, including neuroendocrine modulation via drugs and devices.
  • The goal of these new treatments is to further enhance hypertension management and decrease cardiovascular events.
  • Continuous innovation is essential for improving patient outcomes in hypertension care.
Abstract

Related Concept Videos

What is Evolutionary History?02:35

What is Evolutionary History?

Scientists record evolutionary history by analyzing fossil, morphological, and genetic data. The fossil record documents the history of life on Earth and provides evidence for evolution. However, both fossil and living organisms offer evidence that outlines Earth’s evolutionary history.
43.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
618
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
478
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
513
Life Histories01:29

Life Histories

Overview
22.8K
History of Microbiology01:28

History of Microbiology

Microbiology, a scientific field dedicated to the study of microorganisms, has undergone profound development since its inception in the 17th century. Its history is marked by key discoveries and technological advancements that have shaped our understanding of life at the microscopic level and transformed medicine, agriculture, and industry.Early Foundations of MicrobiologyThe early foundations of microbiology were built on groundbreaking observations and the development of pioneering...
10.4K